18 results about "Blood urate level" patented technology

The application relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition comprises 35-45 parts of a cyclodextrin inclusion compound, 25-35 parts of nano-liposomes, 20-30 parts of a chicory extract-phospholipid complex and 5-8 parts of an antioxidant complex; the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding pueraria extract, drying after inclusion reaction, and obtaining inclusion compound a; step 2, adding hydroxypropyl-gamma-cyclodextrin into water, stirring, adding mulberry leaf extract, drying after inclusion, and obtaining inclusion compound b; and step 3, mixing the inclusion compound a and the inclusion compound b, and obtaining the product. The uric acid reducing composition can more comprehensively and efficiently reduce blood uric acid level, and has high safety, high stability and high bioavailability. The preparation method is simple, easy to industrialize and beneficial to large-scale industrial production.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The application discloses a polypeptide with uric acid reducing activity and a preparation method and application thereof, relates to the field of bioactive peptides, and provides a preparation method of the polypeptide with uric acid reducing activity, which takes whey protein as raw material, and obtains the polypeptide with high activity through directional enzymolysis and ultrafiltration purification, and the polypeptide can reduce blood uric acid level by inhibiting xanthine oxidase activity, and the method has the advantages of high efficiency, low cost and easy implementation, can be implemented on a large scale, and is helpful to improving the utilization value of whey protein in the industry, and provides a new way for the development of functional natural anti-uric acid level abnormality or xanthine oxidase activity abnormality related disease products.

The invention relates to a traditional Chinese medicine composition for treating gout and a pill preparation thereof, the composition takes rhizoma smilacis glabrae and corn stigma as monarch drugs, Chinese actinidia root, fructus polygoni orientalis and the like as ministerial drugs, and erythrina bark, fructus viticis and the like as adjuvant drugs, and the synergistic effect of reducing uric acid and resisting inflammation is realized through scientific compatibility. Experiments show that the preparation can significantly reduce the blood uric acid level of gout model animals, inhibit ankle joint swelling and improve the symptoms of patients through clinical verification, and the safety is superior to that of a traditional western medicine scheme. The technical problems that an existing traditional Chinese medicine preparation is single in target spot and obvious in side effect are solved, and a new solution is provided for gout treatment.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention belongs to the technical field of traditional Chinese medicine modernization and medicine development, and particularly relates to a uric acid reducing product based on folium apocyni veneti extract and application of the uric acid reducing product. The core active component of the product is the folium apocyni veneti extract. In-vivo experiments prove that the extract can remarkably reduce the blood uric acid level and xanthine oxidase (XO) activity of a mouse with hyperuricemia. Six active ingredients entering blood are identified through in-vivo metabolism research. The direct interaction between the main active component and the target protein XO is verified from the molecular level through molecular docking, surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) technologies, and the uric acid reducing action mechanism of the compound is completely clarified. The invention provides a scientific basis and a high-quality product for developing a new uric acid-reducing drug effect of the folium apocyni veneti.

The present invention belongs to the technical field of foods and pharmaceuticals, and relates to a novel use of fucoidan of sporophylls of Undaria pinnatifida. Provided in the present invention is a novel use of fucoidan of sporophylls of Undaria pinnatifida in the preparation of drugs, health foods, and foods for lowering uric acid, which can significantly reduce blood uric acid levels, alleviate and treat gout symptoms, has no toxic side effects, is safe and effective, can be used in the preparation of a URAT1 inhibitor and / or a GLUT9 inhibitor, and can be used in the preparation of drugs, health foods, or foods for lowering uric acid and treating gout, and has broad application prospects.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from semen hoveniae, radix puerariae, semen phaseoli, raw fructus gardeniae, herba taraxaci, poria cocos and rhizoma dioscoreae. According to the traditional Chinese medicine composition, dissolution of effective components is improved through a combined mode of decocting radix puerariae first and decocting other medicines together, dialectical components are adopted, whole-course intervention of upstream generation inhibition, midstream dissolution and crystallization and downstream excretion promotion on hyperuricemia metabolic disorder can be achieved, and the effect of treating hyperuricemia metabolic disorder can be achieved through physique conditioning, heat clearing and diuresis promoting, spleen strengthening and kidney tonifying, detoxification and turbid descending, collateral dredging and blood stasis dissipating. The blood uric acid level and inflammation balance are successfully recovered to a physiological state, and the action mode is superior to a traditional single uric acid reducing strategy and a traditional Chinese medicine application mode of decocting the whole formula simultaneously. In an animal model, the composition has the effects of remarkably reducing uric acid, regulating inflammation, protecting kidney and improving overall physique, the curative effect of a high-dose group is equivalent to that of a classic uric acid reducing medicine allopurinol, and the composition has more advantages in the aspects of kidney pathological repair and long-term safe conditioning.

A postbiotic extract of Lactobacillus plantarum CB102 is prepared by the steps of: subjecting the Lactobacillus plantarum CB102 to a protein extraction treatment, so as to obtain a protein extract; and subjecting the protein extract to a hydrolysis treatment with a protease, so as to obtain the postbiotic extract of Lactobacillus plantarum CB102. The Lactobacillus plantarum CB102 is deposited at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH under an accession number DSM 33894 in accordance with the Budapest Treaty. A method for preparing a postbiotic extract of Lactobacillus plantarum CB102, and methods for reducing a blood uric acid level and alleviating a uric acid metabolism-associated disorder using the postbiotic extract of Lactobacillus plantarum CB102 are also provided.

The application discloses a traditional Chinese medicine combined medicine for treating gout of animals and application thereof, and belongs to the technical field of animal medicine. The core active components of the traditional Chinese medicine combined medicine are composed of astilbin, tanshinone II A and tetrahydrocurcumin, wherein the preferred mass ratio of the components is 4:1:3. Pharmacodynamic researches show that the composition has a significant synergistic effect, can effectively reduce the blood uric acid level of hyperuricemia animals, and synergistically inhibit xanthine oxidase (XOD) activity. Compared with existing chemical medicines, the application reduces the toxic side effects and drug resistance possibility while ensuring efficient reduction of uric acid concentration through synergistic combination of the medicines, provides a safe, efficient and economical new scheme for treating gout of animals, and has important application value.

The invention discloses a uric acid reducing composition based on multi-target synergistic effect and application thereof, and is characterized in that the uric acid reducing composition comprises the following components: tuna peptide extract, gardenia extract, poria cocos extract, chicory extract, celery seed extract, cinnamon extract, kudzu vine root extract, chitosan oligosaccharide, citric acid and vitamin C, the total mass of the tuna peptide extract and the poria cocos extract accounts for 60% or above of the total mass of the composition, and the composition has the advantages that the blood uric acid level can be quickly regulated and controlled, the kidney function is protected, and the inflammatory response is relieved.

This invention discloses a xanthine transporter mutant and its applications, belonging to the field of biotechnology. Using live bacterial cells obtained from recombinant Escherichia coli Nissle 1917 containing xanthine transporter protein cultured in M9 medium as the transporter, and xanthine as the substrate, this invention reduces the extracellular xanthine concentration. Animal experiments showed that gavage administration of the xanthine transporter mutant effectively reduced the xanthine content in the intestine and serum uric acid levels in hyperuricemic mouse models. The invention also discloses that the transport activity of the xanthine transporter mutant changes; in a reaction system containing M9 medium with a final xanthine concentration of 5-20 μg / mL, the transport efficiency of xanthine substrate reaches 83%-100%, and the maximum conversion rate of the substrate is increased by 110-120% compared to the wild type. This invention provides a new treatment method and direction for the treatment of hyperuricemia and various chronic diseases caused by high uric acid.

The invention relates to the technical field of active peptides, and discloses a walnut uric acid reducing active peptide and application thereof. The amino acid sequence of the active peptide is Ser-Phe-Leu-Leu-Ala-Gly-Gly-Glu-Pro-Arg, and the amino acid sequence of the active peptide is shown in the description. The active peptide is prepared by hydrolyzing walnuts through papain, a walnut protein hydrolysate is subjected to mass spectrometric detection, and the active peptide is obtained by screening through a series of computer analysis means such as common peptide fragments, precursor peptides, derivative peptides and molecular docking. The determination of xanthine oxidase IC50 proves that the active peptide screened by the invention has relatively strong uric acid reducing activity. The walnut protein zymolyte containing the uric acid lowering peptide also has better uric acid lowering activity, can be used for preparing uric acid lowering drugs or blood uric acid level control health care products, and also can be compounded with other health care products or food additives for use.

The invention discloses a wheat flavone derivative derived from spartina alterniflora and a preparation method and application thereof. The wheat flavone derivative has a structural expression shown in the specification, the wheat flavone derivative provided by the invention not only can effectively reduce the blood uric acid level, but also can improve metabolic disorders related to hyperuricemia, such as hyperglycemia, hypercholesterol and hypoproteinemia, and has a multi-target effect; .

This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.